Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.75 |
| ▸ | GNAI3 | P08754 | 6/20 | 0.59 |
| ▸ | GNAO1 | P09471 | 6/20 | 0.59 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.59 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL634336 | 1.00 | HRH3 (0.75) | HRH3GNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL1262658 | 1.00 | HRH3 (0.75) | HRH3GNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL11226591 | 1.00 | HRH3 (0.75) | HRH3GNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL11210977 | 1.00 | HRH3 (0.75) | HRH3GNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL9641523 | 1.00 | HRH3 (0.75) | HRH3GNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL23682856 | 1.00 | HRH3 (0.75) | HRH3GNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL1260762 | 1.00 | HRH3 (0.75) | HRH3GNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL1277091 | 1.00 | HRH3 (0.75) | HRH3GNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL22151380 | 1.00 | HRH3 (0.75) | HRH3GNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL11224880 | 1.00 | HRH3 (0.75) | HRH3GNAI3GNAO1GNAI1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1204320-A2 | NOVEL JUVENILE HORMONE ANALOGUES AND THEIR USE AS ANTIFOULING AGENTS | Bioparken AS (NO) | 2002-05-15 | — | — | EP | claimed |
| EP-1204413-A2 | CONTROL OF CRUSTACEAN INFESTATION OF AQUATIC ANIMALS | Bioparken AS (NO) | 2002-05-15 | — | — | EP | claimed |
| WO-2001007047-A2 | CONTROL OF CRUSTACEAN INFESTATION OF AQUATIC ANIMALS | BIOPARKEN AS (NO) | 2001-02-01 | — | — | WO | claimed |
| WO-2001006853-A2 | NOVEL JUVENILE HORMONE ANALOGUES AND THEIR USE AS ANTIFOULING AGENTS | BIOPARKEN AS (NO) | 2001-02-01 | — | — | WO | claimed |
| EP-0317846-B1 | PHARMACEUTICAL AND COSMETICAL COMPOSITIONS BASED ON BENZOYL PEROXIDE AND LIPOPHILIC QUATERNARY AMMONIUM SALICYLATES AND THEIR USE, IN PARTICULAR IN TREATING ACNE | L'OREAL (FR) | 1991-10-16 | — | — | EP | claimed |
| EP-0317846-A1 | Pharmaceutical and cosmetical compositions based on benzoyl peroxide and lipophilic quaternary ammonium salicylates and their use, in particular in treating acne | L'OREAL (FR) | 1989-05-31 | — | — | EP | claimed |
| US-12577344-B2 | One component (1K) composition based on epoxy resin | HENKEL AG & CO. KGAA (DE) | 2026-03-17 | — | — | US | disclosed |
| EP-3916033-B1 | ONE COMPONENT (1K) COMPOSITION BASED ON EPOXY RESIN | HENKEL AG & CO KGAA (DE) | 2025-10-29 | — | — | EP | disclosed |
| US-12338342-B2 | One component (1K) composition based on epoxy resin | HENKEL AG & CO. KGAA (DE) | 2025-06-24 | — | — | US | disclosed |
| US-20240158564-A1 | QUATERNARY AMMONIUM-FUNCTIONALIZED POLYMERS AND METHODS OF MAKING AND USING SAME | U.S. DEPARTMENT OF ENERGY | 2024-05-16 | — | — | US | disclosed |
| CN-114746470-B | One-component (1K) compositions based on epoxy resins | 汉高股份有限及两合公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-117043136-A | Fluorine-based ionic liquid and method for producing same | 第一工业制药株式会社 | 2023-11-10 | — | — | CN | disclosed |
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| EP-0424965-A1 | Amine oxide process | ETHYL CORPORATION (US) | 1991-05-02 | — | — | EP | disclosed |
| EP-0401503-A2 | Solid non-hygroscopic trialkylamine oxides | ALBEMARLE CORPORATION (US) | 1990-12-12 | — | — | EP | disclosed |
| US-4960934-A | Amine oxide process | ETHYL CORPORATION (US) | 1990-10-02 | — | — | US | disclosed |
| EP-0317846-A1 | Pharmaceutical and cosmetical compositions based on benzoyl peroxide and lipophilic quaternary ammonium salicylates and their use, in particular in treating acne | L'OREAL (FR) | 1989-05-31 | — | — | EP | disclosed |
| US-4409198-A | Process for the production of copper (II) chloride from copper (II) oxychloride using tertiary amine hydrochlorides | CHEMISCHE WERKE HULS, AG (DE) | 1983-10-11 | — | — | US | disclosed |
| US-4220764-A | Preparation of tertiary heterocyclic amines | UOP INC. (US) | 1980-09-02 | — | — | US | disclosed |
| US-4179469-A | Preparation of amines | UOP INC. (US) | 1979-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | PLTP, LNPEP, PLIN3 | HRH3 2171/4885GNAI3 1283/4885GNAO1 2211/4885 |
| US-12577344-B2 | One component (1K) composition based on epoxy resin | CBR1, AGTR1, SMARCC1 | HRH3 270/4885GNAI3 3852/4885GNAO1 2266/4885 |
| US-20240158564-A1 | QUATERNARY AMMONIUM-FUNCTIONALIZED POLYMERS AND METHODS OF MAKING AND USING SAME | ALKBH3, ABHD10, ALKBH2 | HRH3 763/4885GNAI3 2945/4885GNAO1 2065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.